Travere Therapeutics, Inc. (TVTX)
TVTX moved a median of -0.19% 30 minutes after news, and -0.24% by the close. How TVTX actually reacts to news — the realized, point-in-time move the market made, measured across 647 labeled events over the last three years with zero look-ahead.
TVTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 48% | 646 |
| 30-min | -0.19% | 41% | 646 |
| 60-min | -0.37% | 44% | 647 |
| to close | -0.24% | 47% | 645 |
| Middle 50% of TVTX reactions | -1.46% to +0.90% |
|---|---|
| Median reaction (30-min) | -0.19% |
| Measured reactions | 647 |
Half of all Travere Therapeutics, Inc. news events land between -1.46% and +0.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TVTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | +4.47% | 73% | +2.01% |
| Analyst downgrades | 11 | +5.58% | 82% | +4.10% |
| Rating reiterations | 137 | 0.00% | 49% | +0.13% |
| Price-target raises | 49 | +0.18% | 55% | 0.00% |
| Price-target cuts | 13 | +2.47% | 54% | +1.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how TVTX ranks against every other measured name →
That’s how TVTX usually reacts — get an email when it moves on news →Email me when TVTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TVTX's baseline. Nothing else.
Recent TVTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.28% | +0.45% | |
| Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 | Press release | Business Wire | +0.79% | +0.48% | |
| Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis | Press release | Business Wire | +0.80% | -0.93% | |
| Form 8-K Travere Therapeutics, For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | +1.26% | -0.15% | |
| Travere Therapeutics Announces Planned Chief Executive Officer Transition | Press release | Business Wire | +1.26% | -0.15% | |
| Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum | Press release | Business Wire | -0.62% | -3.28% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.13% | -0.57% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.02% | -2.21% | |
| Travere Therapeutics to Participate at Upcoming Investor Conferences | Press release | Business Wire | +1.01% | -1.44% | |
| Form 10-Q Travere Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.73% | +1.23% | |
| Form 8-K Travere Therapeutics, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | +1.23% | |
| Travere Therapeutics Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +2.73% | +1.23% | |
| Travere Therapeutics to Report Second Quarter 2026 Financial Results | Press release | Business Wire | -0.60% | -1.65% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.08% | +1.41% | |
| Form 8-K Travere Therapeutics, For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -2.43% | |
| Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | Press release | PR Newswire | -0.68% | +0.10% | |
| Form S-8 Travere Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.06% | +0.11% | |
| Form 8-K Travere Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +2.04% | |
| Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 | Press release | Business Wire | +0.80% | +2.04% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.20% | +5.99% | |
| Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress | Press release | Business Wire | +0.26% | -0.50% | |
| Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases | Press release | PR Newswire | +0.27% | -2.76% | |
| Form 8-K Travere Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | -2.76% | |
| Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases | Press release | Business Wire | +0.27% | -2.76% | |
| Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy | Press release | Business Wire | +0.93% | +0.27% | |
| Form 8-K Travere Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | +0.09% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.46% | +5.00% | |
| Form 8-K Travere Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | -0.65% | |
| Form 305B2 Travere Therapeutics, | SEC filing · Form 305B2 | SEC EDGAR | -0.82% | -1.89% | |
| Travere Therapeutics to Participate at Upcoming Investor Conferences | Press release | Business Wire | -0.82% | -1.89% | |
| Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes | Press release | Business Wire | -1.04% | -5.79% | |
| Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes | Press release | Business Wire | -1.49% | +1.84% | |
| Form 10-Q Travere Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.86% | -3.97% | |
| Form 8-K Travere Therapeutics, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | -3.97% | |
| Travere Therapeutics Reports First Quarter 2026 Financial Results | Press release | Business Wire | -1.86% | -3.97% | |
| Travere Therapeutics to Report First Quarter 2026 Financial Results | Press release | Business Wire | +1.41% | -0.20% | |
| Form 8-K Travere Therapeutics, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | +2.58% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.02% | -3.90% | |
| Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS | Press release | Business Wire | +1.70% | +2.58% | |
| Form ARS Travere Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.59% | +0.76% | |
| Form DEF 14A Travere Therapeutics, For: May 19 | SEC filing · Form DEF | SEC EDGAR | -1.59% | +0.76% | |
| Form DEFA14A Travere Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.59% | +0.76% | |
| Form 10-K Travere Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.04% | +3.09% | |
| Form 8-K Travere Therapeutics, For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -4.04% | +3.09% | |
| Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -4.04% | +3.09% | |
| Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +1.88% | -9.09% | |
| Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.24% | +0.03% | |
| Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit | Press release | Business Wire | -0.51% | -6.95% | |
| Form 8-K Travere Therapeutics, For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -4.63% | -0.41% | |
| Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS | Press release | Business Wire | — | +28.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TVTX section they belong to.
Where else TVTX is measured.
TVTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Travere Therapeutics, Inc.'s median reaction calculated?
Every labeled TVTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 647 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of TVTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TVTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.